Chronic hypoxia during development does not trigger pathologic remodeling of the chicken embryonic heart but reduces cardiomyocyte number.

Fetal growth restriction programs an increased risk of cardiovascular disease in adulthood, but the actual mechanisms of this developmental programming are not fully understood. Previous studies in mammalian models suggest that hearts of growth-restricted fetuses have reduced cardiomyocyte number due to reduced proliferation and premature cardiomyocyte maturation. Chicken embryos incubated under chronic hypoxia are also growth-restricted, have smaller hearts, and show signs of cardiac insufficiency posthatching. The aim of the present study was to investigate how chronic hypoxia (14% O2) during development affects cardiomyocyte mass and how myocardial structure is altered. Hypoxic incubation reproduced the well-characterized embryonic growth restriction and an increased ventricle-to-body mass ratio (at E11, E15, E17, and E19) with reduced absolute heart mass only at E19. Cell density, apoptosis, and cardiomyocyte size were insensitive to hypoxia at E15 and E19, and no signs of ventricular wall remodeling or myocardial fibrosis were detected. Bayesian modeling provided strong support for hypoxia affecting absolute mass and proliferation rates at E15, indicating that the growth impairment, at least partly, occurs earlier in development. Neither E15 nor E19 hearts contained binucleated cardiomyocytes, indicating that fetal hypoxia does not trigger early maturation of cardiomyocytes in the chicken, which contrasts with previous results from hypoxic rat pups. In conclusion, prenatal hypoxia in the chick embryo results in a reduction in the number of cardiomyocytes without inducing ventricular remodeling, cell hypertrophy, or premature cardiomyocyte maturation.

Thyroid hormone does not induce maturation of embryonic chicken cardiomyocytes in vitro.

Fetal cardiac growth in mammalian models occurs primarily by cell proliferation (hyperplasia). However, most cardiomyocytes lose the ability to proliferate close to term and heart growth continues by increasing cell size (hypertrophy). In mammals, the thyroid hormone triiodothyronine (T3) is an important driver of this process. Chicken cardiomyocytes, however, keep their proliferating ability long after hatching but little information is available on the mechanisms controlling cell growth and myocyte maturation in the chicken heart. Our aim was to study the role of T3 on proliferation and differentiation of embryonic chicken cardiomyocytes (ECCM), enzymatically isolated from 19-day-old embryos and to compare the effects to those of insulin-like growth factor-1 (IGF-1) and phenylephrine (PE). Hyperplasia was measured using a proliferation assay (MTS) and hypertrophy/multinucleation was analyzed morphologically by phalloidin staining of F-actin and nuclear staining with DAPI. We show that IGF-1 induces a significant increase in ECCM proliferation (30%) which is absent with T3 and PE. PE induced both hypertrophy (61%) and multinucleation (41%) but IGF-1 or T3 did not. In conclusion, we show that T3 does not induce maturation or proliferation of cardiomyocytes, while IGF-1 induces cardiomyocyte proliferation and PE induces maturation of cardiomyocytes.

Olfactory and visuospatial learning and memory performance in two strains of Alzheimer's disease model mice--a longitudinal study.

Using a longitudinal study design, two strains of Alzheimer's disease (AD) model mice, one expressing ß-amyloid plaques and one expressing Tau protein-associated neurofibrillary tangles were assessed for olfactory and visuospatial learning and memory and their performance compared to that of age-matched controls. No significant difference between AD and control mice was found in the initial set of olfactory tasks performed at 6 months of age whereas both strains of AD mice performed significantly poorer than the controls in visuospatial learning at this age. Subsequent tests performed on the same individual animals at 7, 8, 9, 11, 13, 15, and 18 months of age also failed to find systematic differences in olfactory performance between AD and control mice. In contrast, the AD mice performed consistently poorer than the controls in visuospatial re-learning tests performed at these ages. With most olfactory tasks, both AD and control mice displayed a marked decrease in performance between testing at 15 and 18 months of age. These results show that the two strains of AD model mice do not display an olfactory impairment in a time course consistent with human AD, but are impaired in visuospatial capabilities. The marked age-related changes observed with the olfactory tasks in both AD and control mice suggest that the observed lack of an AD-related olfactory impairment is not due to an insensitivity of the tests employed. Rather, they suggest that the olfactory system of the two AD mouse model strains may be surprisingly robust against AD-typical neuropathologies.